CME Group Beheer
Beheer criteriumcontroles 3/4
De CEO CME Group is Terry Duffy, benoemd in Nov2016, heeft een ambtstermijn van 9.5 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 23.39M, bestaande uit 8.5% salaris en 91.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.025% van de aandelen van het bedrijf, ter waarde $ 26.24M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 9.5 jaar en 17.9 jaar.
Belangrijke informatie
Terry Duffy
Algemeen directeur
US$23.4m
Totale compensatie
| Percentage CEO-salaris | 8.55% |
| Dienstverband CEO | 9.5yrs |
| Eigendom CEO | 0.03% |
| Management gemiddelde ambtstermijn | 9.5yrs |
| Gemiddelde ambtstermijn bestuur | 17.9yrs |
Recente managementupdates
Recent updates
CME: Volatile Street Views And New Futures Will Shape Trading Mix
Analysts have nudged their fair value estimate for CME Group down to $308.20 from $311.67, reflecting slightly softer revenue growth assumptions and a higher discount rate, partly balanced by a higher projected profit margin and a modestly lower future P/E, in line with the mix of recent price target trims and increases across the Street. Analyst Commentary Recent Street research on CME Group has been active on both sides, with several firms adjusting price targets and ratings in different directions.CME Group Q1 Earnings Show Strength, But The Stock Still Looks Expensive
Apr 23CME: Volatility And New Contracts Will Shape Rare Earths And Crypto Volumes
The updated analyst price target for CME Group has moved higher by about $5 to $311.67. This change reflects analysts' use of a slightly lower discount rate, a modestly higher assumed revenue growth rate, and a marginally higher future P/E multiple, even as they factor in a small trim to projected profit margins.CME: Volatility And New Contracts Will Shape Rare Earths And Volume Mix
Analysts have made a modest upward adjustment to the CME Group fair value estimate to about $307 from roughly $305, reflecting slightly revised assumptions for discount rate, revenue growth, profit margin, and future P/E following a mix of recent rating changes and price target tweaks across the Street. Analyst Commentary Recent research on CME Group reflects a mixed but generally balanced backdrop, with several firms adjusting ratings and price targets in different directions.CME: Volatility And New Contracts Will Shape Rare Earths And Clearing Outlook
Our analyst price target for CME Group has moved modestly higher to $305.21 from $299.29, as analysts factor in slightly stronger modeled revenue growth and profitability. This is partially offset by a more conservative future P/E assumption and mixed views on volume drivers across product lines.CME: Volatility And New Contracts Will Shape Futures And Clearing Outlook
The analyst price target for CME Group edges higher to $232, with recent updates reflecting analysts' focus on firmer commodities volumes, as well as a more expense conscious outlook in their refreshed earnings models. Analyst Commentary Recent Street research around CME Group reflects a mix of optimism on volumes and earnings power, alongside caution on valuation and the cost base.CME: Volatility And Prediction Markets Will Guide Futures And Clearing Expansion Outlook
The updated analyst price target for CME Group edges higher to about US$297 from roughly US$290, reflecting analysts' use of a slightly lower discount rate, a modestly higher assumed revenue growth rate, and a similar future P/E multiple despite a slightly lower profit margin input. Analyst Commentary Street research on CME Group in recent sessions centers on a cluster of revised price targets and at least one rating change, with several bullish analysts lifting their targets by varying dollar amounts and one major bank fine tuning its view in both directions over a short time frame.CME: Volatility And Prediction Markets Will Shape Futures Activity Outlook
The analyst price target for CME Group is now US$290.40, a move of about US$2 from the prior US$288.33, as analysts factor in slightly different assumptions for fair value, discount rate, revenue growth, profit margins, and future P/E following mixed recent research that includes both a modest target cut and an upgrade linked to a tilt toward volatility. Analyst Commentary Recent research on CME Group reflects a mix of optimism and caution, with one firm trimming its price target slightly and another upgrading the stock on what it sees as a better setup for volatility related trading activity.CME: Fee Moat And Prediction Markets Will Shape Futures Activity Outlook
Narrative Update: CME Group CME Group's fair value estimate has edged up by about $1 to roughly $288 per share, as analysts cite the company's strong futures and options moat, a higher price target range of up to $314, and interest in its role within prediction markets as key supports for the updated outlook. Analyst Commentary Recent Street research has been generally constructive on CME Group, with several bullish analysts adjusting their price targets higher and highlighting the company's futures and options franchise as a key support for valuation.CME: Fee Resilience And Prediction Markets Will Balance Lower Volatility Risks
Analysts have nudged their average price target on CME Group modestly higher, to approximately $287 from about $286, citing the company’s resilient fee-based revenue mix, strong competitive moat in futures and options, and supportive demand signals from prediction market partnerships despite some conflicting views on near term volume volatility. Analyst Commentary Recent Street research presents a mixed but generally constructive view on CME Group, with upward moves in price targets tempered by concerns around volume sensitivity and valuation risk if volatility normalizes.CME: Fee Resilience And New Prediction Markets Will Help Navigate Volatility
Analysts have raised their fair value estimate for CME Group by about $1 to roughly $286 per share, citing the company’s resilient clearing and transaction fee driven revenue base, modestly higher long term growth expectations, and a reinforced competitive moat highlighted in recent target revisions across the Street. Analyst Commentary Street research on CME Group reflects a wide range of views on valuation and execution, with recent target changes clustering around expectations for resilient fee income but diverging on the sustainability of growth and the impact of lower volatility.CME: Revenue Resilience And New Ventures Will Balance Volatility Risks Ahead
The average analyst price target for CME Group was raised by approximately $3 to $285, as analysts point to the firm's resilient revenue streams and strong market position amid continued macroeconomic uncertainty. Analyst Commentary Recent analyst activity reflects a mix of optimism and caution regarding CME Group's performance and outlook, particularly as the firm navigates shifting macroeconomic and market conditions.CME: More Market Volatility Equals More Demands - Initiating With Strong Buy
Apr 27CME Group At A New All-Time High - Valuation Concerns Justified?
Mar 27CME Group: High Quality With Good Dividend Yield
Feb 18CME Group: Exchanges And Data Will Keep Growing, And So Could Its Dividend
Dec 30CME Group's Dominance Challenged By Now Operational FMX?
Dec 13Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$4b |
| Dec 31 2025 | US$23m | US$2m | US$4b |
| Sep 30 2025 | n/a | n/a | US$4b |
| Jun 30 2025 | n/a | n/a | US$4b |
| Mar 31 2025 | n/a | n/a | US$4b |
| Dec 31 2024 | US$24m | US$2m | US$3b |
| Sep 30 2024 | n/a | n/a | US$3b |
| Jun 30 2024 | n/a | n/a | US$3b |
| Mar 31 2024 | n/a | n/a | US$3b |
| Dec 31 2023 | US$23m | US$2m | US$3b |
| Sep 30 2023 | n/a | n/a | US$3b |
| Jun 30 2023 | n/a | n/a | US$3b |
| Mar 31 2023 | n/a | n/a | US$3b |
| Dec 31 2022 | US$23m | US$2m | US$3b |
| Sep 30 2022 | n/a | n/a | US$3b |
| Jun 30 2022 | n/a | n/a | US$3b |
| Mar 31 2022 | n/a | n/a | US$3b |
| Dec 31 2021 | US$23m | US$2m | US$3b |
| Sep 30 2021 | n/a | n/a | US$2b |
| Jun 30 2021 | n/a | n/a | US$2b |
| Mar 31 2021 | n/a | n/a | US$2b |
| Dec 31 2020 | US$16m | US$2m | US$2b |
| Sep 30 2020 | n/a | n/a | US$2b |
| Jun 30 2020 | n/a | n/a | US$2b |
| Mar 31 2020 | n/a | n/a | US$2b |
| Dec 31 2019 | US$12m | US$2m | US$2b |
Compensatie versus markt: De totale vergoeding ($USD 23.39M ) Terry } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 14.60M ).
Compensatie versus inkomsten: De vergoeding van Terry is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Terry Duffy (67 yo)
Mr. Terrence A. Duffy, also known as Terry, has been Chief Executive Officer and Chairman at CME Group, the world’s leading derivatives marketplace since November 15, 2016. Mr. Duffy is the Chief Executive...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman & CEO | 9.5yrs | US$23.39m | 0.025% $ 26.2m | |
| President & CFO | 3.1yrs | US$4.75m | 0.0066% $ 6.9m | |
| Chief Information Officer | 4.3yrs | US$3.38m | 0.0065% $ 6.8m | |
| Senior MD & Global Head of Commodities Markets | 16.6yrs | US$3.39m | 0.0086% $ 9.1m | |
| Senior MD & Chief Commercial Officer | 19.3yrs | US$3.38m | 0.0083% $ 8.7m | |
| Senior MD | 1.5yrs | geen gegevens | 0.0038% $ 4.0m | |
| MD & Chief Accounting Officer | 11.3yrs | geen gegevens | 0.0070% $ 7.4m | |
| Managing Director of Investor Relations | no data | geen gegevens | geen gegevens | |
| Senior MD & General Counsel | 3.6yrs | geen gegevens | 0.0020% $ 2.1m | |
| Senior Managing Director of Corporate Marketing & Communications | 19.3yrs | geen gegevens | geen gegevens | |
| Senior MD & Chief Human Resources Officer | 18.8yrs | geen gegevens | 0.0092% $ 9.7m | |
| Chief Transformation Officer | 6.3yrs | geen gegevens | 0.0052% $ 5.5m |
Ervaren management: Het managementteam van CME is doorgewinterd en ervaren (gemiddelde ambtstermijn van 9.5 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman & CEO | 31.3yrs | US$23.39m | 0.025% $ 26.2m | |
| Independent Director | 17.8yrs | US$335.67k | 0.00074% $ 776.4k | |
| Independent Director | 32.3yrs | US$288.50k | 0.0069% $ 7.2m | |
| Independent Director | 29.3yrs | US$311.25k | 0.072% $ 76.1m | |
| Independent Director | 26.3yrs | US$301.25k | 0.019% $ 20.2m | |
| Independent Director | 6yrs | US$269.25k | 0.012% $ 12.5m | |
| Independent Director | 18.8yrs | US$337.84k | 0.0016% $ 1.7m | |
| Independent Director | 18yrs | US$316.25k | 0.0031% $ 3.2m | |
| Independent Director | 8yrs | US$312.25k | 0.035% $ 36.7m | |
| Independent Director | 7yrs | US$301.25k | 0.0012% $ 1.2m | |
| Independent Director | 7yrs | US$313.25k | 0.0010% $ 1.0m | |
| Independent Director | 6yrs | US$292.84k | 0.0011% $ 1.2m |
Ervaren bestuur: De raad van bestuur van CME zijn ervaren en ervaren (gemiddelde ambtstermijn van 17.9 jaar).
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/03 10:58 |
| Aandelenkoers aan het einde van de dag | 2026/05/01 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
CME Group Inc. wordt gevolgd door 34 analisten. 13 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Stephen Biggar | Argus Research Company |
| Benjamin Budish | Barclays |
| Roger Freeman | Barclays |